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Background: Genetic effects on asthma of genes in the T-helper 2 (Th2) pathway may interact with epigenetic
factors including DNA methylation. We hypothesized that interactions between genetic variants and methylation in genes
in this pathway (IL4, IL4R, IL13, GATA3, and STAT6) influence asthma risk, that such influences are age-dependent, and that
methylation of some CpG sites changes over time in accordance with asthma transition. We tested these hypotheses in
subsamples of girls from a population-based birth cohort established on the Isle of Wight, UK, in 1989.
Results: Logistic regression models were applied to test the interaction effect of DNA methylation and SNP on asthma
within each of the five genes. Bootstrapping was used to assess the models identified. From 1,361 models fitted at each
age of 10 and 18 years, 8 models, including 4 CpGs and 8 SNPs, showed potential associations with asthma risk. Of the 4
CpGs, methylation of cg26937798 (IL4R) and cg23943829 (IL4) changes between ages 10 and 18 (both higher at 10;
P = 9.14 × 10−6 and 1.07 × 10−5, respectively).
At age 10, the odds of asthma tended to decrease as cg12405139 (GATA3) methylation increased (log-OR = −12.15;
P = 0.049); this effect disappeared by age 18. At age 18, methylation of cg09791102 (IL4R) was associated with higher risk
of asthma among subjects with genotype GG compared to AG (P = 0.003), increased cg26937798 methylation among
subjects with rs3024685 (IL4R) genotype AA (P = 0.003) or rs8832 (IL4R) genotype GG (P = 0.01) was associated with a
lower asthma risk; these CpGs had no effect at age 10. Increasing cg26937798 methylation over time possibly reduced
the risk of positive asthma transition (asthma-free at age 10→ asthma at age 18; log-OR =−3.11; P = 0.069) and increased
the likelihood of negative transition (asthma at age 10→ asthma-free at age 18; log-OR = 3.97; P = 0.074).
Conclusions: The interaction of DNA methylation and SNPs in Th2 pathway genes is likely to contribute to asthma risk.
This effect may vary with age. Methylation of some CpGs changed over time, which may influence asthma transition.
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Asthma is a phenotypically heterogeneous disorder char-
acterized clinically by shortness of breath, wheezing epi-
sodes, chest tightness, and acute episodes of coughing [1].
It affects approximately 235 million people worldwide [2],
with an estimated 5.4 million cases reported in the UK,
including 1.1 million children [3]. While the development
of asthma clearly reflects the combination of inherited* Correspondence: hzhang6@memphis.edu
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etiology is poorly understood and biological mechanisms
underlying its development are not well established.
Variants in genes encoding T-helper 2 (Th2) cytokines,
their receptors, and intracellular signaling pathway com-
ponents have been consistently associated with asthma in
both candidate gene and genome-wide association studies
[5-9]. Interleukin (IL)-4 receptor engagement leads to the
activation of the transcription factor STAT6, which then
upregulates the transcription factor GATA3 [10], which in
turn augments the production of the Th2 cytokines IL-4,
IL-5, and IL-13 [11]. These gene activities may not only beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics for women with available
methylation data compared to the female participants of
the total cohort
Total female
participants
n = 750
Female with DNA
methylation data
n = 245
P values
Factors n (%) n (%)
Asthma at age 18
Yes 128 (19.4) 35 (14.3) 0.07
No 531 (80.6) 210 (85.7)
Missing 91 1
Atopy at age 18
Yes 159 (35.7) 76 (31.4) 0.29
No 287 (64.3) 166 (68.6)
Missing 304 3
Eczema at age 18
Yes 107 (16.3) 37 (15.2) 0.75
No 549 (83.7) 207 (84.8)
Missing 94 1
Rhinitis at age 18
Yes 245 (37.2) 86 (35.1) 0.61
No 413 (62.8) 159 (64.9)
Missing 92 0
Mean (STD) Mean (STD)
Age of asthma onset
at age 18
6.95 (5.43) 8.00 (5.41) 0.11
IgE (log10) at age 18 2.45 (2.84) 2.35 (2.75) 0.57
Zhang et al. Clinical Epigenetics 2014, 6:8 Page 2 of 11
http://www.clinicalepigeneticsjournal.com/content/6/1/8determined by interactions between transcription factors
and cytokine genes, but also affected by epigenetic factors
including DNA methylation [12]. Reduction of DNA
methylation may facilitate transcription through allowing
transcription factors or co-activators to bind to regulatory
elements (promoter or enhancer regions) [13-15]. In gen-
eral, increased DNA methylation of promoter sequences is
associated with decreased gene expression [13]. In con-
trast, intragenic DNA methylation has an inverted U-
shape relationship with gene expression levels, whereby
the highest levels of intragenic methylation are found in
moderately expressed genes [13,16]. However, it is unclear
whether the effect of DNA methylation on gene activity is
also influenced by SNPs on the same gene as the methyl-
ated cytosine-phosphate-guanine (CpG) sites. In addition,
there is a possibility that SNPs far away from a CpG site
can interact with the CpG site to influence a health out-
come, if the SNP is in linkage disequilibrium with another
unmeasured SNP close to the CPG site [17].
Genetic variants and DNA methylation play different
roles in regulating gene expression and hence disease
susceptibility. We have previously shown that inter-
action between genetic polymorphisms and level of
DNA methylation can have “synergistic” effects on risk
of disease susceptibility [18-20]. Therefore, we hypothe-
sized that the interaction of genetic variants and DNA
methylation in at least some of the genes in the Th2
pathway (IL4, IL4R, IL13, GATA3, and STAT6) would be
associated with the risk of asthma, while SNPs may be a
confounder for the main effect of DNA methylation in
some genes. We have demonstrated that, during adoles-
cence, some children grow out of asthma, but new asthma
diagnoses are also observed [21]. We further hypothesize
that association of asthma risk with methylation and with
the interaction between DNA methylation and SNP may be
significant at one age but absent at another. Finally, we pos-
tulate that DNA methylation of some CpG sites changes
over time and that temporal changes of DNA methylation
are associated with asthma transition over time. We test
these hypotheses in subsamples of girls from a population-
based birth cohort established on the Isle of Wight (IOW),
UK, in 1989 that was aimed to prospectively study the nat-
ural history of asthma and allergic conditions.
Results
Comparing the subsample of 245 female participants
with all the 750 female cohort participants, there were
no substantial differences (Table 1). For instance, in the
IOW cohort, 12% of females had asthma at age 10 and
19% had asthma at age 18. In the subset of 245 females
with available methylation data, the corresponding per-
centages were 11% and 14%, respectively. We also com-
pared other related outcomes including rhinitis, eczema,
age of asthma onset, and IgE.We analyzed all available CpG sites in the five genes
(IL4, IL4R, IL13, GATA3, and STAT6) from the Illumina
450 K methylation data and the SNPs that had been geno-
typed in the cohort for these genes. Summary statistics of
these CpG sites and SNPs, including SNP frequencies,
mean, and standard deviation of methylation (β) of each
CpG site at ages 10 and 18, location of each methylation
site, and the corresponding chromosome, are also obtained
and included in Additional file 1: Table S1 and Additional
file 2: Table S2 and Figures S1 and S2.
Selected models at ages 10 and 18 years
At each age of 10 and 18 years, up to 1,361 logistic re-
gression models (following exclusion of missing values)
were fit to the data. Based on the 34 samples with asthma
status and DNA methylation data at age 10 years, this
pathway-based selection process did not select any models
with a significance level of 0.01. This was as expected,
since small samples tend to cause large uncertainty and
thus large P values. We relaxed the significance level and
identified two models showing significance at the level of
0.05. These two models included 2 CpG sites (cg13543854
and cg12405139) and 2 SNPs (rs568727 and rs2229359) in
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cies lower than 5% were observed for SNPs rs568727
(3.23% for AA in age 10 data) (Additional file 1: Table S1),
which is lower than the corresponding population minor
allele genotype frequency (~13% from 1,092 human ge-
nomes [22]). This further supported the use of bootstrap
samples for improving selection accuracy for data with
low frequency categorical variables. Utilizing information
on asthma status and DNA methylation at age 18 years
(n = 245), seven models were identified which either had a
significant methylation effect or a significant interaction
effect on asthma risk. Three CpG sites and 7 SNPs in 2
genes (IL4 and IL4R) were covered by these seven
models (Tables 2 and 3). Two CpG sites (cg09791102
and cg26937798) and 5 SNPs (rs8832, rs1110470,
rs1805011, rs1805012, rs3024685) are in IL4R, 1 CpG
site (cg23943829) and 2 SNPs (rs2070874, rs2243250)
are in IL4. The distances between the identified CpG
sites and the SNPs in each gene are included in Table 4.
The above identified models were internally assessed
using 1,000 bootstrap samples. The selection process
introduced earlier was repeated in each of the 1,000
bootstrap samples and the frequency of each model being
selected in these bootstrap samples was recorded. Based
on the frequencies, we ranked the selected models. For
the models examined using age 10 data, the highest fre-
quency was 27 and it corresponded to the model involving
cg12405139 and rs2229359. For the model containing
cg13543854 and rs568727 identified at age 10, the fre-
quency was 5 out of 1,000 bootstrap samples (Table 5).
Due to the small sample size of the age 10 data, low fre-
quencies were expected. However, findings from the
model with a frequency of 5 should be interpreted with
caution. For the models assessed using age 18 data, the
seven identified models discussed earlier were each with a
frequency higher than 500 and these frequencies were in
the top seven frequencies of all models (Tables 6 and 7).
Among the identified CpG sites, according to the SNP an-
notation file provided by Illumina [23], and further com-
parison with the SNPs from the 1,092 human genomes
(for Caucasians) [22], none of them involve probe SNPsTable 2 Information on the CpG sites in the selected models
Gene CpG sites MapInfo§ Location Chrom.
GATA3 cg12405139 8106035 Body 10
GATA3 cg13543854 8095477 TSS200; TSS1500 10
IL4R cg09791102 27353414 Body 16
IL4R cg26937798 27326054 5’UTR 16
IL4 cg23943829 13200911 TSS1500 5
§MapInfo refers to “genomic coordinates on the human genome” and it gives geno
#Means and standard deviations (SD) are calculated using beta values. Beta values a
$P values are from paired t-tests comparing the difference in DNA methylation between
Mean and SD of DNA methylation of each CpG site are calculated in beta scores.that potentially cause invalid measures of methylation at a
CpG site.
DNA methylation and odds of asthma at ages 10 and 18
At age 10 years, the selected model showed a tendency
that the odds of asthma decreased as the DNA methyla-
tion of cg12405139 increased (log-OR = −12.15 with P =
0.049). The effect of DNA methylation at this CpG site
disappeared at age 18 (Table 5). For CpG site cg13543854,
based on age 10 data, subjects with genotype CC with an
increase of DNA methylation also had an increased odds
of asthma compared to subjects with genotype AC (P for
the interaction effect = 0.04). However, due to the low fre-
quency in which its corresponding model was selected in
1,000 bootstrap samples, this finding should be interpreted
with caution. At age 18, of the CpG sites and SNPs in the
seven selected models, some were potential risk factors
and others were possibly protective (Tables 6 and 7). For
IL4R, methylation at cg09791102 was a risk factor (models
2 and 3 in Table 6, log-OR = 3.27 with P = 0.007, and log-
OR = 3.34 with P = 0.006). The interaction of methylation
at site cg09791102 with the rs1110470 genotype GG
(model 1, P = 0.003) suggested that the DNA methylation
of this site was associated with higher risk of asthma
among girls with genotypes GG compared to girls with
genotype AG (Table 6). Within IL4R, the interaction of
cg26937798 with rs3024685 and with rs8832 (models 4
and 5, P = 0.003 and 0.01, respectively) indicated that in-
creased DNA methylation of this site among subjects with
the rs3024685 genotype AA or rs8832 genotype GG was
associated with a lower risk of asthma. It is worth noting
that none of the CpG sites showing a significant inter-
action with SNPs is close to those SNPs (Table 5). We also
observed that rs1805011 and rs1805012 in IL4R were po-
tential confounders in that they do not statistically signifi-
cantly interact with CpG site cg09791102, however,
cg09791102 became an insignificant factor (P = 0.51) if
these two SNPs were excluded (data not shown). For IL4,
DNA methylation of cg23943829 was protective (models 6
and 7 in Table 7; log-OR = −3.60 with P = 0.009, and log-
OR = −4.47 with P = 0.003, respectively). These CpG sitesbefore bootstrapping
Mean at age 10 (SD)# Mean at age 18 (SD)# P value$
0.93 (0.0008) 0.92 (0.011) 0.12
0.047 (0.007) 0.042 (0.008) 5.84 × 10−3
0.94 (0.046) 0.94 (0.050) 0.14
0.076 (0.022) 0.062 (0.013) 9.14 × 10−6
0.88 (0.016) 0.86 (0.019) 1.07 × 10−5
mic location.
re used to measure DNA methylation levels of each CpG site.
ages 10 and 18 years on logit-transformed beta values (to approximate normality).
Table 3 Genotype frequencies of the SNPs included in the selected models before bootstrapping based on age 18 SNP data
Gene SNP Genotype n/N (%) at 18 years* Gene SNP Genotype n/N (%) at 18 years*
GATA3 rs568727 AC 95/213 (44.60) IL4R rs1805012 AG 44/231 (19.05)
CC 92/213 (43.19) GG 5/231 (2.16)
AA 26/213 (12.21) AA 182/231 (78.79)
GATA3 rs2229359 AG 30/234 (12.82) IL4R rs3024685 AG 104/231 (45.02)
GG 202/234 (86.32) GG 42/231 (18.18)
AA 2/234 (0.85) AA 85/231 (36.80)
IL4R rs8832 AG 111/233 (47.64) IL4 rs2070874 AG 61/231 (26.41)
GG 71/233 (30.47) GG 170/231 (73.59)
AA 51/233 (21.89) AA —
IL4R rs1110470 AG 112/227 (49.34) IL4 rs2243250 AG 63/228 (27.63)
GG 70/227 (30.84) GG 165/228 (72.37)
AA 45/227 (19.82) AA —
IL4R rs1805011 AC 47/232 (20.26)
CC 5/232 (2.15)
AA 180/232 (77.59)
*SNP frequencies at age 10 years are available in Additional file 1.
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age 10 data, but did not show any significant main or
interaction effects (Tables 6 and 7).
DNA methylation change and asthma transition
Before presenting the findings of the association of DNA
methylation changes with asthma status transitions, we
focus on the 4 CpG sites included in the selected models
and first discuss the stability of DNA methylation at these
CpG sites (cg12405139 [GATA3], cg09791102 [IL4R],
cg26937798 [IL4R], and cg23943829 [IL4]) between ages
10 and 18. The level of DNA methylation at each of these
4 CpG sites is consistent between the two ages in that, if aTable 4 Distance of the selected CpG sites to the
selected SNPs
SNP Distance of CpG sites from a SNP (bp)
IL4 cg23943829
rs2070874 −599
rs2243250 −43
IL4R cg09791102 cg26937798
rs8832 −22,373 −49,733
rs1110470 +16,987 −10,373
rs1805011 −20,458 −47,818
rs1805012 −20,550 −47,910
rs3024685 −23,496 −50,856
GATA3 cg13543854 cg12405139
rs568727 −11,224 −666
rs2229359 −5,170 +5,388
+means CpG located after SNP; − CpG located before SNP.site was highly methylated at age 10, then it was also
highly methylated at age 18. Further results from paired t-
tests indicated that methylation of two CpG sites,
cg12405139 and cg09791102, does not show any statisti-
cally significant changes between the two ages (Table 2),
while methylation of CpG sites cg13543854, cg26937798,
and cg23943829 at age 10 is statistically significantly
higher than the methylation of these two sites at age 18
(means of pair differences in the logit scale are 0.14, 0.24
and 0.17 with P = 5.84 × 10–3, 9.14 × 10−6, and 1.07 × 10−5,
respectively; Table 2).
For the CpG sites where methylation is stable between
ages 10 and 18 years, we evaluated the association of
asthma transition with DNA methylation at age 18, SNP,
and their interaction. No significant main or interaction
effects were identified (Table 8). For the 2 CpG sites
where methylation changed between ages 10 and 18 years
(cg23943829 and cg26937798), we evaluated the associ-
ation of asthma transition with change of DNA methyla-
tion between 10 and 18 years, SNP, and their interaction.
Although we did not detect a statistically significant
interaction effect, the increase of DNA methylation of
cg26937798 over time had a tendency to reduce the risk
of positive transition (log-OR = −3.11; P = 0.069) and in-
creased the likelihood of negative transition (log-OR =
3.97; P = 0.074, Table 8).
Discussion
As previously demonstrated, interactions between DNA
methylation and SNPs may show a stronger effect com-
pared to the effects of SNPs alone on the risk of asthma
[18,19]. Utilizing a comprehensive assessment of the
Table 5 The effects of SNP, DNA methylation, and their interactions in selected models (GATA3)
Effects at age 10 (n = 34) Effects at age 18 (n = 233)
Model Model frequency# Parameter Estimate (log OR) P value$ Estimate (log OR) P value$
1 5 cg13543854 −20.27 0.19 3.21 0.066
rs568727 AA NA NA 27.47 0.37
CC 123.62 0.04 −11.50 0.20
AC Ref. Ref. Ref.
cg13543854* rs568727 AA NA NA 9.42 0.36
CC 40.76 0.04 −3.52 0.21
AC Ref. Ref.
2 27 cg12405139 −12.15 0.049 −0.02 0.99
rs2229359 AG −47.21 1.00 −13.86 1.00
AA NA NA −22.39 0.36
GG Ref. Ref. Ref.
cg12405139* rs2229359 AG 12.15 1.00 0.02 1.00
AA NA NA 8.58 0.37
GG Ref. Ref. Ref.
#The frequency is based on 1,000 bootstrap samples.
$P values significant at the 0.01 level at age 18 are in bold font.
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and their interactions in genes within the Th2 pathway,
we identified CpG sites such that their main effects or
interaction effects with SNPs were potentially associated
with the risk of asthma. We also explored whether the
changes of methylation between ages 10 and 18 is associ-
ated with the asthma transition. Based on our knowledge,
this is the first study to systematically assess the DNA
methylation effects and their interaction with SNPs in the
Th2 pathway on asthma risk and, more importantly, the
first study testing the effect of temporal change of DNA
methylation on asthma transition between ages 10 and 18.
We examined CpG sites and SNPs in 5 genes (IL4, IL4R,
IL13, GATA3, and STAT6) related to Th2 immunity. Test-
ing the effects of genetic and epigenetic variants targeted
at a specific asthma-related pathway has the potential to
gain a higher statistical power compared to the unbiased
approach of investigating the whole genome. The CpG sites
and SNPs were selected based on a consideration of main
methylation effect and the interactions between methyla-
tion and SNPs. In total, seven models based on age 18 data
were identified. For the age 10 data, we did not identify any
statistically significant models based on significance level
0.01, but did detect two models possibly of interest at sig-
nificance level 0.05. Through further internal validation
using 1,000 bootstrapping samples, one of the two models
identified at age 10 was with low selection frequency while
all the seven identified models from the age 18 data were
with a frequency higher than 500 out of 1,000. In total,
these models included 5 CpG sites and 9 SNPs. An alterna-
tive approach to select models is a direct utilization of boot-
strap samples: first using bootstrap samples to improve theestimates of standard errors of effect estimates, and then
identifying models based on improved test statistics [24].
We found that the methylation of individual CpG sites
provided limited evidence of associations with asthma
status. In contrast, the interaction effects between SNPs
and DNA methylation of those CpG sites were statistically
stronger. For instance, cg09791102 was an insignificant
factor by itself (P = 0.51). However, this CpG site showed a
significant interaction effect with rs1110470 and became a
potential risk factor for girls with genotypes GG compared
to AG (model 1, P = 0.003; Table 6). All the CpG sites
showing a significant interaction with SNPs were not close
to the SNPs, indicating possible biological independence
between those CpG sites and SNPs. A recent study indi-
cated that such observation might also be due to these
SNPs being in linkage disequilibrium with SNPs close to
those CpG sites [17]. We further noticed that rs1805011
and rs1805012 in IL4R were potential confounders in that
they do not statistically significantly interact with CpG site
cg09791102; however, cg09791102 became an insignificant
factor (P = 0.51) if these two SNPs were excluded.
The model identified using age 10 DNA methylation data
and asthma status information indicated a substantial
decrease in the odds of asthma along with the increase of
DNA methylation of cg12405139 (log-OR = −12.15 with
P = 0.049). Although its corresponding P value was not sig-
nificant at the significance level of 0.01, the statistical sig-
nificance was completely lost (P = 0.99) when evaluating
age 18 data. In contrast, the seven selected models based
on age 18 data were not significant to data collected at age
10. It is possible that this lack of association at age 10 was
due to small sample size (n = 34). On the other hand, the
Table 6 The effects of SNP, DNA methylation, and their interactions in selected models (IL4R)
Model Model frequency# Parameter Effects at age 10 (n = 34);
Log-OR (P value)
Effects at age 18 (n = 233);
Log-OR (P value$)
1 570 cg09791102 8.29 (0.53) −0.70 (0.2)
rs1110470 AA 42.92 (0.33) −3.93 (0.6)
GG 55.34 (0.24) −25.00 (0.004)
AG Ref. Ref.
cg09791102* rs1110470 AA −13.96 (0.34) 1.42 (0.6)
GG −18.83 (0.23) 8.51 (0.003)
AG Ref. Ref.
2 546 cg09791102 −6.52 (0.18) 3.27 (0.007)
rs1805011 AC −36.87 (1.00) 16.62 (0.02)
CC 22.14 (1.00) −5.22 (1.00)
AA Ref. Ref.
cg09791102* rs1805011 AC 6.51 (1.00) −5.88 (0.02)
CC NA −3.27 (1.00)
AA Ref. Ref.
3 571 cg09791102 −6.52 (0.18) 3.34 (0.006)
rs1805012 AG −36.87 (1.00) 17.16 (0.02)
GG 22.14 (1.00) −5.01 (1.00)
AA Ref. Ref.
cg09791102* rs1805012 AG 6.52 (1.00) −6.03 (0.02)
GG NA −3.34 (1.00)
AA Ref. Ref.
4 633 cg26937798 −4.91 (0.23) 1.53 (0.3)
rs3024685 AG 22.65 (0.11) −24.15 (0.002)
GG −4.59 (1.00) 0.62 (0.9)
AA Ref. Ref.
cg26937798* rs3024685 AG 8.63 (0.11) −8.37 (0.003)
GG 4.91 (1.00) 0.09 (0.9)
AA Ref. Ref.
5 761 cg26937798 0.01 (1.00) 0.09 (0.9)
rs8832 AA −16.93 (1.00) 10.38 (0.07)
GG −29.34 (0.59) −20.81 (0.01)
AG Ref. Ref.
cg26937798* rs8832 AA −0.01 (1.00) 3.73 (0.09)
GG −11.56 (0.59) −7.23 (0.01)
AG Ref.
#The frequency is based on 1,000 bootstrap samples.
$P values significant at the 0.01 level at age 18 are in bold font.
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methylation for two methylation sites (cg23943829 and
cg26937798) between ages 10 and 18. This indicates that
the significant effects of these two sites or the effects
of their interaction with SNP on asthma status at age 18
were likely to be due to change of methylation over time.
A possible explanation is that methylation levels at some
CpG sites were dynamic during the period of adolescenttransition and were only associated with disease status at
one time point. We also observed that at some CpG sites
the effects of DNA methylation or its interaction with
SNPs were attenuated at age 18 (Tables 6 and 7). Since the
sample size at age 10 is much smaller than that at age 18,
a larger variation in the age 10 data was expected. A fur-
ther investigation to assess the attenuation is needed in
larger samples. Furthermore, although we did not detect
Table 7 The effects of SNP, DNA methylation, and their interaction effects in selected models (IL4)
Model Model frequency# Parameter Effects at age 10 (n = 34);
Log-OR (P value)
Effects at age 18 (n = 233);
Log-OR (P value)$
6 532 cg23943829 −2.17 (1.00) −3.60 (0.009)
rs2070874 AG −22.16 (1.00) −4.97 (0.4)
GG Ref. Ref.
cg23943829* rs2070874 AG 2.17 (1.00) 2.61 (0.4)
GG Ref. Ref.
7 669 cg23943829 −1.60 (0.64) −4.47 (0.003)
rs2243250 AG −21.18 (1.00) −6.75 (0.2)
GG Ref. Ref.
cg23943829* rs2243250 AG 1.60 (1.00) 3.84 (0.1)
GG Ref. Ref.
#The frequency is based on 1,000 bootstrap samples.
$P values significant at the 0.01 level at age 18 are in bold font.
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change (from ages 10 to 18) for cg26937798 and its corre-
sponding SNPs, the tendency of methylation increase of
cg26937798 over time reducing the risk of positive transi-
tion and increasing the likelihood of asthma remission is
informative and certainly deserves further investigation.
The selection of CpG sites and SNPs was based on a
model selection approach with each model composed of
one CpG site and one SNP. To further assess the findings,
we used 1,000 bootstrap samples to internally validate the
identified CpG sites. The bootstrapping technique has been
studied and used in various studies for the purpose of in-
ternal validation and shown to be effective [25]. The exclu-
sion of the model involving cg13543854 and rs568727 due
to a low frequency of selection among the 1,000 bootstrap
samples indicates that this model, identified based on the
original data, is likely to be a random finding. Overall, the
findings from this work provided insight into the under-
standing of the impact of methylation on asthma at a single
time point (ages 10 or 18) and on asthma transition be-
tween ages 10 and 18.Table 8 The effects of changes in DNA methylation on
asthma transition between ages 10 and 18
Gene CpG sites Effects on transition; Log-OR (P value)
(−,+)# (+,–)$
Dynamic methylation
GATA3 cg13543854 1.69 (0.22) −0.58 (0.78)
IL4R cg26937798 −3.11 (0.069) 3.97 (0.074)
IL4 cg23943829 3.56 (0.11) −0.99 (0.73)
Stable methylation
GATA3 cg12405139 −1.60 (0.64) 1.06 (0.71)
IL4R cg09791102 −21.18 (1.00) −0.67 (0.47)
#(−,+): positive transition of asthma between ages 10 and 18 years.
$(+,–): negative transition of asthma between ages 10 and 18 years.We did not perform technical replicates on DNA methy-
lation analyses. However, various studies have shown its
overall congruence with quantitative pyrosequencing [26],
validated its robustness via cancer cell lines [27], and con-
firmed the quality of pre-processed methylation data [28].
Another potential limitation exists in the influence of cell
composition on the measure of DNA methylation. DNA
methylation obtained from peripheral blood leukocytes
served as surrogate measures of cell mixture distribution
[29]. These surrogate measures might introduce noise in
the association studies presented in our work and conse-
quently cause power loss in our inferences. However, the
estimates are still expected to be unbiased as seen in the
modeling proposed earlier [29]. In the logistic regression
for identifying CpG sites and SNPs potentially associated
with asthma, each model included one CpG site and one
SNP in their corresponding gene. Since SNP × SNP and
CpG×CpG interactions may also exist, there is a possibility
that our selection might have overlooked some potentially
important CpG sites or SNPs due to interaction effects.
Multiple testing was not corrected using the commonly
used methods such as the method controlling for false dis-
covery rate. We, instead, used the methods built upon
bootstrapping to further assess the selected models as in
previous studies. It has been shown, and also seen in our
recent simulation studies, that the false discovery rate-
based multiple testing correction method cannot control
for type I error [30,31]. However, this type of concern will
be minimal when the sample size is large. In addition, this
study only included girls. Gender difference in DNA
methylation has been noted in various studies [32-35]. It is
possible that the identified CpG sites associated with
asthma or its transition are different if analyzed in boys.
Finally, since this is the first study that examined the
methylation change during adolescent transition and its
association with asthma status transition, a further valid-
ation study in a comparable population and a thorough
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with other adjusting factors are needed. These further
investigations need careful epidemiological and biological
justification, and are our on-going work.
Conclusions
The interaction of DNA methylation and SNPs in Th2
pathway genes contribute to the risk of asthma, but effects
may not be stable over time. DNA methylation of some
CpG sites changes over time and DNA methylation change
has the potential to influence asthma transition.
Methods
Data collection
The study cohort was composed of children born between
January 1, 1989 and February 28, 1990 on the IOW, UK, a
semi-rural island without heavy industry near the UK
mainland [36]. Of the 1,536 children born and recruited in
this period, 1,456 were available for further follow-up. In
follow-ups, data were collected at ages 1, 2, 4, 10, and 18
years. Questionnaires that included the questions of the
International Study of Asthma and Allergy in Childhood
(ISAAC) [37] were administered at each follow-up. In
the case that parents or participants could not attend a
follow-up visit to complete the questionnaire, a modified
version was given either over the telephone or via mail. In-
formation such as disease status (e.g., asthma, eczema,
and rhinitis), age of asthma onset, puberty events, and
smoking status were collected based on responses to the
questionnaires.
Peripheral blood samples for DNA isolation were col-
lected at ages 10 and 18 years. At age 18 years, saliva sam-
ples were also collected. Genotyping was conducted on
samples from 1,211 cohort subjects. DNA methylation of
CpG sites was determined in DNA extracted from periph-
eral blood leucocytes collected at 18 years of age from 245
female cohort participants. These 245 participants were
randomly selected from the 750 female cohort participants
for screening of epigenetic associations with allergic disor-
ders in a mother-infant study. Random sampling was used
to reduce bias in the subsample. Of these 245 women, we
randomly sampled 16 individuals with asthma and 18 indi-
viduals without, and obtained their DNA methylation at
age 10 measured from peripheral blood leucocytes.
The outcome considered was occurrence of asthma at
ages 10 and 18 based on the questions of ISAAC [37]. It was
defined as having “ever had asthma” and either “wheezing or
whistling in the chest in the last 12 months” or “current
treatment for asthma”. Wheezing was defined as wheezing
or whistling in the last 12 months.
Transition of asthma status
We consider two types of asthma transitions, positive
and negative, from ages 10 to 18. Asthma status wastreated as a binary variable (0/1), so at each age a partici-
pant was classified either as asthma-free (0) or as having
asthma (1). A subject experienced positive transition of
asthma if he/she was asthma-free at age 10 but had
asthma at age 18. Negative transition (also called remis-
sion) occurred when an asthma patient outgrew the dis-
ease at age 18.
The SNPs and CpG sites in the five genes
We selected SNPs potentially related to asthma by use
of a tagging strategy for each of the five genes in the
Th2 pathway (IL4, IL4R, IL13, GATA3, and STAT6). In
this tagging strategy, SNPs that had previously been as-
sociated with asthma and/or were potentially functional
variants were prioritized. Specifically, Tagger imple-
mented in Haploview using HapMap Caucasian data
was used to develop the tagging scheme across each
gene including 10 kb upstream and downstream of each
gene with r2 of 0.85 as the tagging threshold. Genotyp-
ing was conducted on DNA extracted from blood or sal-
iva samples for 1,211 cohort subjects using GoldenGate
Genotyping Assays (Illumina, Inc., CA, USA). Details of
genotyping are reported elsewhere [18].
For methylation analyses, DNA was extracted from
whole blood using a standard salting out procedure [38].
DNA concentration was determined by PicoGreen dsDNA
quantitation kit (Molecular Probes, Inc., OR, USA). One
microgram of DNA was bisulfite-treated for cytosine to
thymine conversion using the EZ 96-DNA methylation kit
(Zymo Research, CA, USA), following the manufacturer’s
standard protocol. Genome-wide DNA methylation was
assessed using the Illumina Infinium HumanMethyla-
tion450 BeadChip (Illumina, Inc., CA, USA), which inter-
rogates >484,000 CpG sites associated with approximately
24,000 genes. Arrays were processed using a standard
protocol as described elsewhere [39], with multiple identi-
cal control samples assigned to each bisulfite conversion
batch to assess assay variability and samples randomly dis-
tributed on microarrays to control against batch effects.
The BeadChips were scanned using a BeadStation, and the
Methylation Module of GenomeStudio (Version 2011.1)
software calculated the methylation level for each queried
CpG as beta (β) values. They represent the proportions of
intensity of methylated (M) over the sum of methylated
and unmethylated (U) sites (β = M/[c + M + U] with con-
stant c introduced for the situation of too small M + U).
The methylation data were then preprocessed using the
Bioconductor IMA package and the ComBat function in R
for initial quality control to remove unreliable CpG sites,
correct for probe types, remove background noise, and
correct for batch effect [40,41]. DNA methylation of 100
CpG sites and 42 SNPs were available for the genes IL4,
IL4R, IL13, GATA3, and STAT6 and included in the ana-
lyses. Specifically, 5 CpG sites and 4 SNPs for IL4, 10 CpG
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IL13, 67 CpG sites and 17 SNPs for GATA3, and 9 CpG
sites and 1 SNP for STAT6 were epityped and genotyped.
Statistical analysis
To assess whether the analytical sample (245 female par-
ticipants) was representative of the female cohort available
at age 18 years, we applied two types of tests. The χ2 tests
were used to assess the agreement between the subsample
(n = 245) and the female cohort on the prevalence of
asthma, atopy, eczema, and rhinitis. Two sample t-tests
were used to assess the agreement on IgE and ages of
asthma onset.
To identify statistically significant interaction effects on
asthma among the candidate CpG sites and SNPs on these
five genes, logistic regression models were applied. Asthma
status was the dependent variable and SNPs, DNA methy-
lation in logit transformed β values, and their interaction
were the independent variables. For each gene, we consid-
ered models formed by all possible combinations between
SNPs and methylation sites. For instance, 67 CpG sites and
17 SNPs were available for GATA3 and thus 1,139 (67 CpG
sites × 17 SNPs) logistic regression models were fitted for
GATA3. Models that showed either statistically significant
main effects of DNA methylation or significant interaction
effects of DNA methylation and SNPs were chosen as can-
didate models.
To evaluate methylation changes between ages 10 and
18 on the selected CpG sites, paired t-tests were applied
to logit-transformed methylation values. To evaluate
whether DNA methylation change at the selected CpG
sites was associated with the odds of asthma transition
(positive and negative) with respect to no asthma at both
ages while taking SNP effects into account, logistic re-
gressions were applied to test the effects of methylation
change, SNP, and their interaction. For CpG sites where
DNA methylation did not change over time, we evaluated
whether DNA methylation or its interaction with SNPs
was associated with the odds of asthma transition (positive
and negative) compared to no asthma at both ages. In this
direction, logistic regressions were also used and DNA
methylation at age 18 of the selected CpG sites along with
corresponding SNPs were included in the analyses.
Since the selection of the genes was guided by biological
pathways, the CpG sites were not independent. To take the
multiple testing into account while admitting the depend-
ence between tests in this selection process, we set the sig-
nificance level at a lower level, specifically, 0.01, aiming to
identify models with possibly significant CpG sites and
SNPs. To further assess the identified models, bootstrap-
ping was then used to evaluate the identified models at
each age. Each bootstrap sample was created based on ran-
dom sampling by drawing with replacement and the size
of each bootstrap sample is the same as in the originalsample. In total, 1,000 bootstrapping samples were used,
logistic regression models with all possible combination of
CpG sites and SNPs within a gene were fitted to each sam-
ple, and the relative frequency of each selected model out
of 1,000 bootstrapping samples was recorded. The boot-
strapping technique used for variable and model selection
was proposed in the 1990’s [42] and has been discussed
and applied in different studies [43,44]. In our study, since
minor allele frequencies for some SNPs were low, using
bootstrap samples had the potential to reduce the bias on
variable selections due to large variations in the estimation
of variances caused by low minor allele frequencies. We
note that models with CpG sites involving probe SNPs
would not be considered due to biased measures of DNA
methylation. The significance level of 0.05 was used for the
remaining tests with respect to the identified CpG sites
and SNPs; these tests include t-tests and logistic regres-
sions. All the statistical analyses were performed using the
R statistical computing package [45].
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